Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

By Yoko S Derose, Guoying Wang, Yi-Chun Lin, Philip S. Bernard, S. Buys, Mark T. W. Ebbert, R. Factor, C. Matsen, Brett Milash, Edward W. Nelson and 6 more. Nature Medicine, 2011

950 citations recorded by the source corpus.

Development and preclinical testing of new cancer therapies is limited by the scarcity of in vivo models that authentically reproduce tumor growth and metastatic progression. We report new models for breast tumor growth and metastasis in the form of transplantable tumors derived directly from individuals undergoing treatment for breast cancer. These tumor grafts illustrate the diversity of human breast cancer and maintain essential features of the original tumors, including metastasis to specific sites. Co-engraftment of primary human mesenchymal stem cells maintains phenotypic stability of the grafts and increases tumor growth by promoting angiogenesis. We also report that tumor engraftment is a prognostic indicator of disease outcome for women with newly diagnosed breast cancer; orthotopic breast tumor grafting is a step toward individualized models for tumor growth, metastasis and prognosis. This bank of tumor grafts also serves as a publicly available resource for new models in which to study the biology of breast cancer.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0095ca8e6fe00eaac2b9d1c0e43febde47dd2334

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform (2016, background): “…tumorgrafts capture the heterogeneity of cells in a tumor, and in some cases, the tumor histomorphology and global gene expression profile (DeRose et al., 2011); however, engraftment into a mouse or matrix material exerts a selection pressure that changes the clonal composition (Luca…”
Patient Derived Xenograft Models: An Emerging Platform for Translational Cancer Research (2014, background): “Patients with human breast cancer, RCC, PDAC, and uveal melanoma whose tumors successfully engraft show the worst prognosis, indicating that there is a selection toward more aggressive higher metastatic tumors (14, 15, 22, 30, 33, 61).”
Patient-derived tumor xenografts: transforming clinical samples into mouse models. (2013, background): “breast cancer grafts showed that metastasis frequencies varied between 38% and 100% depending on the tumor type (13).”
Dynamics of genomic clones in breast cancer patient xenografts at single cell resolution (2014, neutral): “T X1 X2 X3 X4 X5 Cluster (n) 1 (66) 2 (12) 3 (10) 4 (8) 5 (5) 6 (3) SA500 (Prim.”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “For example, fat pad transplanted breast cancer PDX samples grown in NOD-SCID mice resemble the architecture of the original tumors, promote vascularization, and mimic metastatic behavior observed in patients (DeRose et al. 2011).”
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. (2012, neutral): “0) (28); BRCA1 BLCs from Institut Bergonié (9 cases; Illumina 660K).”
Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “…significantly inhibited the growth of three preestablished, patient-derived tumors, engrafted orthotopically into immunodeficient mice (Figure 4D) (DeRose et al., 2011) Low-DoseDAC Inhibits GenePromoter DNAMethylation and Causes Re-Expression of Hypermethylated Genes The ability of transient low…”
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response (2015, neutral): “1 SS (54) PDAC (61) EC (12) OVC (42) RCC (19) BRCA (56) CRC (72) NSCLC (42) CM (44) 1.”